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Summary in English 
Background 
More than half the world’s population is colonized with Helicobacter pylori (H. pylori) in the 
gastric mucosa which is the major cause of chronic gastritis and peptic ulcer. Moreover,  H. 
pylori has been associated  with the development of non-cardia gastric cancer, the second 
leading cause of cancer-related deaths worldwide, and has been linked to extra-intestinal 
diseases, with unsettled causal relationships. The human host immune response is unable to 
clear the H. pylori infection, and the clinical phenotype is dependent on the interactions 
between the host immune response and the pathogenicity of the bacterium. The prevalence of 
H. pylori infection is greatly reduced in developed countries but can be as high as >90% in 
underdeveloped countries, and remains a great health problem world-wide.  
Aims 
In a population based study from two North Norwegian cohorts, we aimed to 
- describe the association between H. pylori infection and reflux disease, functional 
bowel symptoms and obesity 
- describe the all age prevalence of H. pylori 
- describe potential transmission routes of H. pylori  
Results 
We found that H. pylori is protective against reflux symptoms in men but not in women, 
whereas obesity was an independent risk factor for reflux symptoms in women. Functional 
bowel symptoms are prevalent in the population, and female gender, high body mass index 
and low age, but not H. pylori infection, are risk factors for the condition. There was no 
association between H. pylori infection and body mass index including being obese. In our 
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populations with presently apparent high hygiene status,  the transmission of H. pylori 
infection may start also in the adolescence, has a peak in adults, and potential transmission 
routes are out-door toilette, private well and farm animals but not as independent factors in 
multivariance analyses.  
Conclusion 
In the start of the 21
st
 century it seems that the H. pylori infection may start also in the 
adolescents, and has its peak in adults, and the transmission is associated to low hygiene 
standards.  H. pylori infection is associated with reflux symptoms in men, but not with 

















Sammendrag på norsk 
Bakgrunn 
Over halvparten av verdens befolkning er infisert med bakterien Helicobacter pylori i 
magesekkens slimhinne. Denne bakterien er hovedårsaken til kronisk magekatarr og magesår. 
Helicobacter pylori er assosiert med utvikling av kreft i magesekken, og med utvikling av 
tilstander utenfor tarmsystemet hvor årsaksammenhengen er ukjent. Vertens immunrespons 
greier ikke å fjerne Helicobacter pylori infeksjonen, og de forskjellige sykdomstypene er 
derfor karakterisert ved interaksjoner mellom vertens immunrespons og bakteriens evne til å 
skape sykdom. Forekomsten av Helicobacter pylori infeksjonen er de siste tiår kraftig 
redusert i industrialiserte land, mens den er såpass høy som > 90 % in utviklingsland, og den 
er fortsatt et helseproblem verden over.  
Målsettinger 
I denne befolkningsbaserte studien fra to nordnorske kommuner er målsettingene å beskrive 
- Sammenhenger mellom Helicobacter pylori infeksjonen og reflukssykdom, 
funksjonelle mageplager og overvekt 
- Forekomsten av Helicobacter pylori i alle aldersgrupper 
- Mulige smitteveier til Helicobacter pylori 
Resultater 
Studien viser at Helicobacter pylori virker beskyttende mot reflukssymptomer hos menn, men 
ikke hos kvinner, mens overvekt er en uavhengig risikofaktor for refluks symptomer hos 
kvinner. Funksjonelle tarmplager er utbredt hos unge voksne kvinner, men disse plagene har 
ikke sammenheng med Helicobacter pylori. Det var ingen sammenheng mellom Helicobacter 
pylori infeksjonen og kroppsmasseindeks inklusiv overvekt. I befolkninger med høy 
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hygienestandard, ser det ut som om smitte av Helicobacter pylori starter først i tidlig 
ungdomstid, mens forekomsten er størst hos voksne, og mulige smitteveier er via utedo, privat 




I det 21 århundre viser våre data at Helicobacter pylori infeksjonen starter først i tidlig 
ungdomstid, forekomsten er størst blant voksne, og smitten er assosiert til ulike hygieniske 
faktorer. Helicobacter pylori infeksjonen er assosiert til reflukssymptomer hos menn men 





Presently, over half the world’s population is colonized with Helicobacter pylori (H. pylori), 
which is the major cause of chronic gastritis and peptic ulcer (1). H. pylori has also been 
associated with the development of non-cardia gastric cancer, which is the second leading 
cause of cancer-related deaths worldwide (2). H. pylori infection has also been linked to 
extra-intestinal diseases, yet with unsettled causal relationships (3). The host immune 
response is unable to clear the H. pylori infection, and the clinical phenotype is dependent on 
the interactions between the host immune response and the pathogenicity of the bacterium. 
The prevalence of H. pylori infection is greatly reduced in developed countries but can be as 
high as >90% in underdeveloped countries (4). The infection can be effectively cured by 
antibiotics combined with acid inhibitors (5), but still remains a challenge for 
gastroenterologists world-wide.  
 
1.1 H. pylori infection from ancient times to the final discovery 
Infection with H. pylori has co-evolved with mankind since the Paleolithic era (5).  Thus, both 
humans and H. pylori migrated from East Africa around 58 000 years ago (6), (7).  
The spiral-shaped microorganism later identified as H. pylori was noticed in the human 
stomach by the clinical researcher Jaworski at Krakow University, Poland in 1899 (8) after    
Bizzozero had found spiral organisms in dogs in 1893 (9). The main crucial events of our 
knowledge of H. pylori came in 1979-82 by the groundbreaking experiments of the two 
Australian scientists, the pathologist Robin Warren who identified the bacterium underneath 
the protecting lining mucus coat in the stomach, and Barry Marshall that finally, albeit 
accidentally, successfully cultured the bacterium (10), (11) . In 1985, Marshall reported H. 
pylori to be the cause of gastritis (12). Finally, Borody in 1987 was the first to document that 
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H. pylori caused peptic ulcer disease by developing the triple therapy (bismuth, metronidazole 
and tetracycline) used in the eradication of H. pylori (13), (14). This has later been reported as 
“Marshall found the bug and Borody the drug”. 
 
 1.2 H. pylori microbiology 
The Helicobacter genus includes more than 35 species. H. pylori, the most important human 
pathogen, is Gram-negative, spiral shaped, acid-resistant and microaerophilic. Research 
boomed heavily after 1997, when Tomb and co-workers published the entire H. pylori 
genome (15).  
 
Thus, H. pylori can be described as a cross between a commensal and a pathogenic bacterium.  
Typically, all Helicobacter species express urease enzymes, an enzyme that is essential for 
microbial survival (16). Experimental deletion of the urease gene renders H. pylori unable to 
colonise gastric mucosa (17).(18). The function of urease is to increase pH in the 
microenvironment by the generation of ammonia (NH3) from urea and to secure the nitrogen 
supply for bacterial protein production (19). Urease is an intracellular enzyme that is bound to 
the outer membrane of other bacteria upon bacterial lysis. These non-covalently bound 
proteins may in turn impair the function of secretory IgA directed against H. pylori by antigen 
shedding. However, all clinical isolates produce urease and thus it cannot explain the 
occurrence of clinical disease.  
 
Several pathogenic bacterial factors have been identified which may have impact on the 
clinical presentation, but the only factors with consistent impact in laboratory and clinical 
studies were cytotoxin-associated gene A (CagA) and vacuolating cytotoxin gene (VacA). 
Both of these factors can be detected in strains from asymptomatic carriers. However, their 
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contributions to H. pylori-related pathology are academically interesting, but the overall 
impact is small. Alternatively, the main determinant may be differences between immune 
phenotypes of the infected individuals.  
 
Today the most thoroughly documented pathogenic factor of H. pylori is CagA (20). The 
functions of the CagA protein is not fully understood, but several lines of evidence indicate 
that the protein is a phosphatase capable of altering activation states of proteins and 
transcription factors like NFκB in the target cell (21). 
All H. pylori strains contain the VacA gene, but five different genotypes exist rendering 
approximately 50% of the strains VacA protein negative. The VacA has been shown to induce 
vacuolization of epithelial gastric cell lines (16). 
 
1.3 The source and transmission routes of H. pylori 
The source or sources of H. pylori are so far unknown, and subsequently the knowledge of the 
transmission routes is limited. Faecal animal H. pylori has been one of the most frequent 
proposed sources (22), and the primary transmission route has been proposed to be via 
drinking water, and the secondary to be intra-familiar H. pylori infection (23). The 
transmission routes have been proposed to be combinations of oral-oral, gastro-oral or faecal-
oral transmission due to lack of access to clean drinking water and proper sanitation as 
proposed by Khalifa (24).  
 
Both water and food have been proposed to be the primary source of H. pylori (for review, see 
(25)). H. pylori DNA can be detected in water using different methods (26), (27), and this has 
facilitated several studies dealing with water as a source of transmission. The animal source 
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for contamination drinking water has been proposed to be mice (22). Food has been suggested 
to be a vehicle rather than a source of H. pylori (28). 
 
The understanding of intra-familiar H. pylori infection was increased with the introduction of 
multi-locus sequence typing (MLST). This technology allows for the assessment of genomic 
profiles of H. pylori isolates from infected families. MLST can identify the original strain 
infecting the index person. In one report, a mother to child transmission could be detected in 
three of four families, and father-child and child-child transmission could also be documented 
(29). Transmission from mother to child and sibling to sibling has also been documented by 
Yokota (30). It is noteworthy that the oral cavity can be a reservoir of H. pylori (31), and it is 
also of interest that vaginal yeast is an important primary reservoir of H. pylori, thus 
explaining transmission to neonates (32).  
   
The question of whether breast-feeding is a transmission route from mother to child, or the 
opposite: whether breast-feeding can protect from H. pylori infection, is unanswered. Most 
studies agree that the latter is the case. In a meta-analysis, breast feeding had a protective 
effect in a less economically developed setting (33).  However, in one report, H. pylori DNA 
was found at a rate of 6.1% in breast milk, but there remained a question whether this was due 
to a contamination from the nipples (34). 
 
1.4 H. pylori diagnosis 
Various tests have been developed to diagnose H. pylori that display varying accuracy, 
specificity and feasibility for use in clinical practice or in research. This can be analytical tests 
for detection of HP antigen or antibodies, detection of urease production, histological 
detection or culture of the HP. The various tests have various advantages and disadvantages, 
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and the choice of test(s) to be used is dependent on many factors such as for clinical or 
research use.  In general the tests need either an intervention such as a biopsy from an 
endoscopic examination, or a peripheral test such as blood tests for detecting HP antibodies, 
or antigen and/or antibodies tests from samples from saliva, urine and faeces, or detection of 
urea in expired breath air.  
 
In clinical practice, a blood test for the detection of H. pylori antibody or the test for H. pylori 
antigen in feces are most often used, both being non-invasive. The former has the 
disadvantage that antibodies are present in blood also after eradication of the bacterium. The 
invasive tests mostly used in clinical practice are the rapid urease test and histological 
detection, both performed in biopsies from gastric mucosa. The former test can be false 
negative when bacterial growth is inhibited due to the use of acid suppression medication.  
 
In clinical research, there is a need for extensive documentation of H. pylori using a 
combination of several tests, both invasive and non-invasive. For epidemiological studies, the 
serum H. pylori antibody tests are widely used. However, this has been challenged by the 
introduction of the fecal antigen test, which is more practical to perform and more reliable 
than the antibody test. For more details, see Chapter 1.5 (for review, see (35)).   
 
1.5 H. pylori epidemiology  
There is a marked difference in prevalence between developed and underdeveloped countries 
(36). Numerous epidemiological studies of H. pylori infection based on various registration 
methods such as cohort examinations exist, but only population-based studies will give a real 
estimate of the prevalence in a community. Only a few population-based prevalence studies in 
children and adolescents exist, in contrast to the larger number of studies in adults.  Many of 
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the population studies have used serological testing (37), (38), a method with known 
limitations as described above. Lately, studies have also been published that use the urea 
breath test (UBT), which is practical for population studies (39), (40).  
Studies in children  
Only a few population-based prevalence studies have been published that include children  
(41), (42), (43), and especially studies using modern precise methods are scarce. Serology-
based studies from Europe have shown prevalence in children from 1.2% in the Netherlands 
(44) to 32% in Polish children (38). Reports from USA have revealed prevalence of 7.1% (45) 
up to 29% (46). 
 
The UBT is more precise and feasible in children (47), and UBT-based studies from Europe 
have reported prevalence in Germany from around 6% (48) and 8.6% in Ireland. An 
American study revealed a prevalence of 17% in children (49). The highest occurrence of H. 
pylori infection have been reported from Asia, with prevalence found from 13.1% in Hong 
Kong (42) to around 50% in Turkey (50), and 64.2% in Iran (51).  
 
Stool tests from asymptomatic subjects in Europe have revealed a prevalence of 27% in 
children of Turkish descent in Germany aged 1 to 4 (52), and 7.1% in children aged 0 to 15 in 
the Czech Republic (41). In Uganda, investigators found a prevalence of 44.3 in 
asymptomatic children aged 0 to 12 (53).  
 
Studies amongst adolescents 
Prevalence studies in adolescents are harder to find. In Siberia, the seroprevalence in youths 
aged 14 to 17 was 56.3% (54), and in a follow-up study from Turkey in the age group 9 to 18, 
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the prevalence based on UBT was around 50% (55). A German study found a prevalence of 
6.5% in 14-year old adolescents (56).  
Studies in adults 
The prevalence of H. pylori infection in adults has been studied much more extensively. Most 
studies are based on serological tests. The first report from our region was that of  Bernersen  
et al in 1987 (57), who used bacterial culture and found a prevalence of 41.8%. A follow-up 
study 17 years later reported 25% (58). In a North American study one found a 
seroprevalence of 17.1% in symptomatic patients (59), and studies from Iran (60) and Brazil 
(61) have found prevalence of 69% and 63%, respectively.  
 
UBT-based prevalence studies are considered more precise than serology studies, but are 
more cumbersome to perform. European UBT-based studies have reported prevalences of 
42% in all age groups 5-100 years in the Czech Republic (62) and 58% in Italy in age groups 
18-80 (63). A study from Turkey found a prevalence of 82.5% in asymptomatic adults (64), 
and another study from USA found 52% (65).  
 
Stool tests are not often used in adult studies, but a Japanese study using both serology and 
stool tests found a prevalence of approximately 40% (66). In Borneo, a stool test-based study 
revealed a prevalence of 37.7% (67). A Northern Norwegian methodology study found a 
prevalence of 44.3% in dyspeptics (68). 
 
1.6 H. pylori infection and gastric pathogenicity 
H. pyloritypically colonizes the gastric mucosa with the development of histological gastritis 
in all infected subjects. However, the infection induces various clinical phenotypes depending 
on bacterial factors, host factors and environmental factors. It is of interest that only a 
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minority of the infected patients have symptoms, 10-20 % develops peptic ulcer disease, and 
less than 2% develop gastric cancer.    
Acute and chronic gastritis.  
Colonization of H. pylori in the gastric mucosa induces inflammation, especially in the 
antrum and corpus part of the stomach. This chronic active gastritis is the pathophysiological 
mechanism of the H. pylori-associated disorders as described below. 
 
There are only a few reports of acute gastritis, but some knowledge is based on established 
experimental human models (69). Thus, H. pylori infection is known to give some transient 
dyspeptic complaints, and transient hypochlorhydria, i.e. the reduction of acid secretion. 
Whether the acute gastritis can spontaneously be resolved is unknown. 
 
When the H. pylori colonization becomes persistent, there is a more pronounced, lasting 
reduction of acid secretion, and the more extended the inflammation is, the greater is the 
reduction of secretion. There is a counteractive effect of acid secretion on the H. pylori 
growth. In patients with somewhat normal acid secretion, H. pylori colonization and the 
chronic gastritis is found in the gastric antrum where there is an absence of acid secreting 
parietal cells. In patients with more profound reduction of acid secretion, the gastritis moves 
proximally towards the gastric corpus, leading to pan-gastritis with the suppression of parietal 
cell function. The reduced acid secretion is counteracted initially by several mechanisms such 
as hypergastrinemia (for review, see (35)) 
Atrophic gastritis and gastric cancer  
The consequence of H. pylori-associated chronic gastritis may eventually be loss of normal 
gastric architecture, with the transformation of the gastric mucosa towards intestinal 
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metaplasia (intestinal-type epithelium) and fibrosis. Atrophic gastritis occurs in approximately 
50% of H. pylori-infected patients, and especially in those with severe inflammation (70). The 
risk factors for developing atrophic gastritis beyond that of the intensity of H. pylori infection 
are not fully understood.  
 
The association and causal relationship between H. pylori-associated atrophic gastritis, 
metaplasia and gastric cancer was first shown in studies of gastric cancer. Here, this 
pathophysiological sequence was more frequently seen when infection was present than in the 
uninfected controls (71). The causal relationship between H. pylori infection and gastric 
cancer has been established after extensive investigation (for review, see (35)). The risk of 
developing gastric cancer when infected by H. pylori is estimated to be increased by 10 fold 
compared to non-infected persons. Moreover, the extensive eradication of H. pylori the last 
decade in Western countries parallels the reduction of the incidence of gastric cancer. Yet a 
causal relationship is highly controversial, and even not documented in some studies (72).   
H. pylori and peptic ulcer disease 
Before the nineteenth century, peptic ulcer disease – the common name for gastric and 
duodenal ulcer disease – was rare (73). From that time the prevalence of gastric ulcers 
increased, and around 1850 the first duodenal ulcers were reported. The diagnoses were based 
on physical examination, patient history and the presence of postprandial pain, as X-ray was 
not invented before 1895. Medical therapy was limited, and surgery was the main treatment 
up to the 1960s. 
 
The cause of peptic ulcers remained a mystery for many decades, although several theories 
evolved. The Croatian physician Karl Schwartz published his theory of “no acid, no ulcer” 
(74) in 1910. Until the 1980s, the peptic ulcer disease was described as a multi-heterogeneous 
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disease with mucosal disturbances, vascular disturbances, infectious and/or toxic and 
psychogenetic as the most often reported causes (73). 
 
The causal relationship between H. pylori infection and peptic ulcer disease was documented 
after extensive investigation subsequent to the discovery of the bacterium. In the first studies, 
H. pylori infection was found in 95% of patients with duodenal ulcer and in 85% in gastric 
ulcer patients. The life-time risk of developing peptic ulcer in H. pylori infected patients is 3 
to 10 times higher than in non-infected patients (75). Finally, eradication of H. pylori became 
an efficient way to cure peptic ulcer disease (76). 
 
One unexplained question is that why only some 10-20% of the infected patients develop 
peptic ulcer disease during a long term follow-up (77). This has been proposed to rely on 
bacterial and/or host factors.  
H. pylori and non-ulcer dyspepsia 
Non-ulcer, or functional, dyspepsia (NUD), is defined as pain or discomfort from the upper 
gastrointestinal tract without documentable structural abnormalities. The association of H. 
pylori infection to non-ulcer dyspepsia has been extensively investigated. In a cohort of 
patients with dyspepsia, 30-60% will have H. pylori infection. However, the non-infected 
control group also has also a similar symptom rate (78). Therefore, there has been much 
debate of what will be the expected outcome of H. pylori eradication in patients with 
dyspepsia. In a meta-analysis of NUD, H. pylori eradication was associated with an 8% risk 
reduction compared to placebo, and the conclusion was that one had to eradicate H. pylori in 
18 patients to achieve relief of dyspeptic symptoms in one patient (79). However, the 
Maastricht IV guidelines now recommend eradication in patients with functional dyspepsia, 
especially in high-prevalent regions (80). 
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 1.7 H. pylori and gastro-oesophageal reflux disease 
The prevalence of Gastro-Oesophageal Reflux Disease (GORD) is as high as 60% in many 
countries, and 10-20% have symptoms weekly (81). There are several potential risk factors 
for GORD, such as age, smoking, and life style factors with Body Mass Index (BMI) as the 
mostly proposed risk factor (82). Although extensively investigated, the contribution of 
overweight and obesity to GORD is still not clarified. When comparing the few strictly 
population-based studies, BMI was found to be independently associated to GORD in some 
studies (83), (84) but not in others (85), (86). 
 
The role of H. pylori in GORD is also somewhat controversial, as both the presence and the 
absence of an association have been reported (87-89) A population-based study from 2007 has 
shown that H. pylori infection was not a risk factor for reflux symptoms (90). Finally, the 
interaction between BMI and H. pylori infection in the contribution to GORD is unsettled, as 
far as we know.  
 
1.8 H. pylori and functional bowel diseases 
Functional gastrointestinal disorders comprise a family of closely related symptom patterns 
describing pain or discomfort related to ingestion or digestion of food, often in the absence of 
a known organic cause. Functional bowel disease or Irritable Bowel Syndrome (IBS) 
according to the Rome criteria are possibly the most studied of these symptom patterns. IBS is 
a syndrome of constant or recurring abdominal pain or discomfort related to bowel 
movements, in the absence of biomarkers or endoscopic findings (91).  IBS can be diagnosed 
according to the Rome II (92) or Rome III criteria (93). The prevalence of IBS is reported to 




The cause of IBS is unclear, but etiological factors such as genetic, food intolerance and gut 
microbiology including post-infection IBS has been proposed, with visceral hypersensitivity 
as the common pathophysiological mechanism (94).  
 
The association between H. pylori infection and IBS is not settled. H. pylori infection has 
been shown to be a risk factor for IBS in one study (95), but not in three other reports (96), 
(97), (98). There are, however, no larger, population-based studies that have addressed this 
issue. 
 
1.9  H. pylori and body weight 
The increasing prevalence of overweight and obesity from the 1980s in the developed world 
has a parallel in the decreasing prevalence of H. pylori and the increased use of antibiotics for 
its eradication. This has initiated a debate of a causal relationship between H. pylori infection 
and body mass index (BMI). Cross-sectional studies have shown an association between H. 
pylori infection and BMI (99), (100)whereas the the National Health and Nutrition 
Examination Survey (NHANES III) could not detect any association (101).In a large 
population-based, randomised controlled trial, significant weight gain (3 kg) was observed in 
the intervention group that underwent H. pylori eradication. Unfortunately, follow-up was 
only for 6 months. In an animal study, H. pylori colonization was shown to decrease weight 
gain (102). Finally, in a recent published review, the authors concluded that the increasing 
eradication of H. pylori during the last decade was a contributing causal factor to the obesity 
epidemic in the Western world (103). The H. pylori hypothesis explaining the obesity 
endemic is fascinating. Further support of this causal relationship is found in the report 
showing that eradication of H. pylori in non-dyspeptic patients caused an increase in plasma 
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ghrelin, the hunger hormone(104).  In conclusion, there is some evidence of a causal 
relationship between H. pylori infection and BMI, but there is a need of further studies, 
especially population based, cross-sectional and prospective studies.  
 
1.10 Unresolved questions and challenges 
As described above, since the identification of H. pylori in 1970-80s, much knowledge has 
been gained of the epidemiology, pathophysiology and clinical phenotype of this infection. 
Maybe one of the most interesting unresolved questions is why only 10-20% of the H. pylori-
infected patients develop peptic ulcer disease. Moreover, H. pylori behaves in some way as a 
commensal bacterium, and in other times as a pathogenic bacterium. Finally, the source and 
ways of transmission of the bacterium are still unsettled. 
 
H. pylori infection is also associated to extra-gastroduodenal disorders, some of which have 
been described above. Further disorders that have been associated with H. pylori infection are 
coronary heart disease, dermatological disorders, autoimmune thyroid diseases and others (for 
review, see (35)). For these possible associations there are many controversies, and the 
associations may have several explanations. In general, association studies should be 
performed in large scale, population-based studies. Most of the discrepancies described above 
may be explained by the lack of such studies. 
 
Therefore, major focus of H. pylori in the 21
st
 century should be on the sources and 
transmission routes, and on potential association of the infection with extra-gastroduodenal 
disorders to find any existing causal relationships. 
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2. AIMS OF THE THESIS 
Despite extensive investigations there are many unresolved questions and discrepancies in the 
understanding of H. pylori infection. Therefore, to gain more knowledge, I have in the my 
doctoral thesis focused on the following hypotheses: 
 
1. There is an association between H. pylori infection and reflux disease 
2. There is an association between H. pylori infection and functional bowel disease 
3. There is an association between H. pylori infection and obesity 
4. The low prevalence of H. pylori in the start of the 21st century is due to low transmission 
risk in young age groups.  
5. H. pylori transmission is associated with low hygienic standards, i. e. animal contact, 







3. SUMMARY OF RESULTS 
 
3.1 Paper I 
Breckan RK, Paulssen EJ, Asfeldt AM, Mortensen L, Straume B, Florholmen J. The impact of 
body mass index and H. pylori infection on gastro-oesophageal reflux symptoms: A 
population-based study in Northern Norway. Scand J Gastroenterol. 2009, 10:1-7.  
 
The aim of this study was to evaluate the effect of BMI and  H. pylori on reflux symptoms in 
an adult population. For this cross-sectional, population-based study from Bodø and Sørreisa 
communities in Northern Norway, a total of 3927 adults were invited to complete a 
questionnaire on gastrointestinal symptoms and to provide stool samples for the assessment of 
H. pylori. Reflux symptoms were considered present when a reflux syndrome score was >2 
according to the Gastrointestinal Symptom Rating Scale (GSRS).  
The response rate was 44.2%, and 44.7% of the respondents were male. There were similar 
characteristics in the two populations studied, but in the more rural population in Sørreisa the 
prevalence H. pylori infection was slightly higher than in the urban population of Bodø (28.9 
% versus 35.0 %, but not significant after Bonferroni correction).  In logistic regression 
analyses, H. pylori and smoking were not risk factors for reflux symptoms, whereas male 
gender (OR 4.78 (95%CI 1.88; 12.1)), age (1.01 (1.00; 1.03)) and overweight (1.51 (1.14; 
2.00)) were. When stratified by gender, overweight and age were independent risk factors for 
reflux symptoms in females only, whereas H. pylori infection was protective against such 
symptoms in men. Models including these parameters could only explain 3% of the variations 




The strength of this study is that it is population based , and that validated questionnaires have 
been used. It should be noted that a low-threshold definition of reflux symptoms (mean GSRS 
reflux symptom score) was chosen in order to compare our findings with those of other 
reports, as in the prevalence of 26% for reflux symptoms found in a Danish population(105)]. 
In a study from Italy, reflux symptoms were found in 44.3% of the participants (106), whereas 
in a Swedish population-based study there was a prevalence of 40.0% (107), both using 
different questionnaires. Our results may thus be somewhat conservative, yet comparable to a 
review that found at least monthly reflux symptoms in 25% of participants (108). 
In conclusion, BMI is an independent risk factor for gastro-oesophageal reflux symptoms 
among healthy female adults, but contributes only to a minor part of the variation in these 
symptoms. H. pylori is protective against reflux symptoms in men. 
 
 
3.2 Paper II 
Breckan RK, Asfeldt AM, Straume B, Florholmen J, Paulssen EJ. Prevalence, comorbidity, 
and risk factors for functional bowel symptoms: a population-based survey in Northern 
Norway. Scand J Gastroenterol 2012, 47, 1274-82.  
 
The objective was to assess the occurrence of functional bowel (FB) symptoms in Northern 
Norway, and to describe gender differences, comorbidity, and association to risk factors, 
including H.  pylori infection.  
 
Adult subjects (18–85 years) from the communities Bodø and Sørreisa were invited to 
complete a questionnaire on gastrointestinal symptoms, and to provide stool samples for 
assessment of H. pylori. 
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Of the 3927 invited subjects, 1731 (44.1%) returned the questionnaire and 1416 (36.0%) 
provided stool samples. Functional bowel symptoms were found in 25%, somewhat more 
frequent in females (28.6%). Symptom pattern differed between genders only with regard to 
constipation. Presence of FB symptoms was significantly associated with gastro-esophageal 
reflux symptoms, headache, dizziness, palpitations, sleep disturbances, and musculoskeletal 
symptoms. Psychometric traits were also more prevalent: feeling of low coping ability, 
feeling depressed, feeling of time pressure, and a low self-evaluation of health. In a 
multivariate regression model, factors that influenced the reporting FB symptoms were male 
gender (OR 0.71, 95% CI (0.52; 0.96)), age 50–69 years or ‡70 years (OR 0.49 (0.30; 0.80) 
and 0.40 (0.21; 0.79)), obesity (OR1.61 (1.05; 2.47)), NSAID use (OR2.50 (1.63; 3.83)), and 
previous abdominal surgery (OR1.54 (1.05; 2.26)). The presence of H. pylori was not 
associated with FB symptoms.  
 
The strength of this study is the sampling of symptoms in a general population. Although 
invitation to participate in a study of a certain ailment is prone to select those who have such 
symptoms, we are aware of this and have taken measures to adjust for such a bias. The 
weakness is the use of a non-validated questionnaire for the assessment of symptoms that 
mimic irritable bowel syndrome. IBS is defined as a presence of traits with a duration 
sufficiently long to give it a chronic nature, whereas the questions in the GSRS form samples 
the severity of symptoms present in the last week. By transforming a symptom severity score 
into symptom prevalence we have extended the original intention of the GSRS form, thus the 





We conclude that functional bowel symptoms are prevalent, but our findings may be prone to 
self-selection bias. FB symptoms carry a significant burden of comorbidity. Female gender 
and low age are known risk factors for FB symptoms, NSAID use as a risk factor deserves 
further clarification, whereas H. pylori infection was not associated with FB symptoms.  
 
 
3.3 Paper III  
Breckan RK, Paulssen EJ, Asfeldt, AM, Kvamme JM, Mortensen L, Straume B, Florholmen J. 
The all-age prevalence of H. pylori infection and potential transmission routes in a 
population-based study. Submitted Helicobacter 2015. 
 
Previous research on H. pylori epidemiology has mostly focused on adult populations. In this 
combined urban and rural community, population-based, and all-age prevalence study, the 
aim was to study H. pylori prevalence in all age groups including children, and to identify 
potential transmission routes of the bacterium.  Subjects from all age groups (children 0-11 
years, adolescents 12-17 years and adults 18->80  years of age) recruited from both an urban 
and a rural community in Northern Norway were invited to deliver stool samples for the 
diagnosis of H. pylori antigen and to fill in a questionnaire (adult and adolescents only) on 
gastrointestinal  symptoms, lifestyle factors and biometric data.                                                                                                                              
 
A total of 1 624 (35.3%) of the invited subjects including 173 (39.3%) of the children, 45 
(19.2%) in the adolescents group, and 1 416 (36.1%) in the adults group, responded to the 
invitation. H. pylori infection was nearly undetectable (0.6%) among the children and the 
prevalence increased from adolescents (20.0%) to adults towards 45% at the highest age 
group. A broad screening for potential transmission routes showed that ever having a private 
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water source, an outhouse toilet in childhood, or contact with farm animals, was significantly 
associated to H. pylori positivity in univariate analyses. However, no independent risk factor 
could be identified in the multivariate analyses. Our data indicate that the transmission routes 
in the 21
st
 century may be related to life-style factors in adolescence.  
 
The strength of this study is the population-based prevalence measurements including all age 
groups, from both an urban and a rural community. Moreover, we have based our data on an 
antigen-based H. pylori test, with known high sensitivity and specificity. Yet there are areas 
with some weakness. Firstly, the participation from the adolescence group was low. The 
prevalence data of H. pylori infection from this group thus remains uncertain, but the lowest 
possible prevalence would still be 3% if all the 205 non-participating subjects had tested 
negative. Therefore, we have evidence from this study that H. pylori infection first occurs at a 
very early age. Another weakness of our study is that more comprehensible data would have 
been available if a family-based prevalence study had been performed in the H. pylori positive 
subjects.  
 
In conclusion, in our populations with presently apparent high hygienic status the 
transmission of H. pylori infection first starts not only in childhood, but also in the 
adolescence, where potential transmission routes may be out-door toilette, private well and 






4. GENERAL DISCUSSION 
4.1 Methodological considerations 
This is a population based urban study from two communities in North Norway, The Bodø 
Helicobacter study and the Sørreisa Gastrointestinal Disorder Study address a general 
Norwegian, adult population. 
4.1.1 Participation, questionnaire and sampling of stool test 
A representative sample from the urban part (population 24,625 in January 2005) of Bodø 
municipality was drawn by Statistics Norway (http://www.ssb.no/english/), consisting of 480 
persons aged 18-29 years and 200 from each of five 10-year strata: 30-39, 40-49, 50-59, 60-
69 and 70-79 years, all together 1480 individuals were invited to participate.  
4.1.1.1 Adults 
The study population from Sørreisa (population 3326) has been described previously (58). In 
short, 2447 persons (all adults aged 18 to 85 years in the community) were invited to 
participate in 2004. 
 
Both populations were invited to answer the same questionnaire on gastrointestinal disorders, 
lifestyle factors and biometric data, as well as to provide stool samples. The questionnaire is 
presented in Appendix 1. 
 





Table 1. Participation and HP status in the Bodø Helicobacter study and Sørreisa 
Gastrointestinal Disorder Study.  
Numbers (%) Bodø Sørreisa Bodø + 
Sørreisa 

















Responder        
male % 
41 46 44.7 
Responder mean 
age 
51.4 51.9 51.7 
HP positive (%) 145 (29) 321 (35) 466 (33) 
 
4.1.1.2 Children and adolescents 
In addition, population-representative groups of 440 children between 0 and 11 years of age, 
and 240 adolescents 12-17 years old in Bodø were invited. The children - rather their 
guardians – were asked to provide a stool sample, whereas the adolescent subjects were asked 
to fill in a simplified questionnaire (Appendix 1) and to deliver a stool sample as for the adult 
subjects. No questionnaire was used among the children. One child (0,06%, a girl) and 7 





Table 2. Response rates among children and adolescents in the Bodø Helicobacter Study.  
Age group  Invited Stool samples Questionnaires 
 N M/F n (%) M/F n (%) M/F 
0-11 years 440 220/220 173 (39.0) 92/81 n/a n/a 
12-17 years 240 120/120 35 (14.6) 18/17 45 (18.8) 22/23 
 
Over-all and gender distribution of response rate (n, percent) to the invitation to fill in a 
questionnaire (adolescents only) and provide stool samples for the detection of H. pylori in 
the Bodø Helicobacter Study. An equal number of males (M) and females (F) were invited. 
 
4.1.2 Potential bias 
Statistical bias occurs when the results are distorted by systematic differences in the studied 
samples. I will concentrate on potential pitfalls in this thesis with focus on selection bias, 
information bias and confounding, especially as we have pooled data from two studies, and 
that very young participants (adolescents) were included. 
4.1.2.1 Selection bias 
Selection bias is defined as selecting individuals for analysis without achieving a 
representative selection – a selection that matches the population that the research aims to 
study.  As the sample in this study was selected by Statistics Norway and not by the 
researcher, selection bias due to participant selection procedures is less likely. The Statistics 
Norway selection included an equal distribution of individuals of all ages, gender and of 
socioeconomic backgrounds. However, the individuals who chose to respond to the survey 
and submit stool samples may not fully represent the source population regarding these 
factors. This is accounted for by presenting the results in age, gender and socioeconomic 
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categories. As mentioned before, the attendance rates of the surveys ranged from 33.8% to 
48.8% in the adult group (table 1) and from 14.6% to 39.3% for children and adolescents 
(table 2). These numbers are not as high as can be seen in plain questionnaire-based studies, 
but taking into consideration that the respondents were asked to submit their personal human 
waste, it is reconciling that so many individuals from rather small geographic areas chose to 
participate. In comparison, an H.pylori study from Leeds using the much less intimate Urea 
Breath Test ended up with a response rate of 25% (109). That being said, this project’s study 
sample could favourably be larger. 
4.1.2.2 Information bias 
To avoid information bias, defined as measuring different samples using different methods, 
the same laboratory technicians examined all the stool samples, and the utilised techniques 
did not differ from sample to sample. Furthermore, the same questionnaire was sent to every 
subject. The quality or accuracy of the information gathered about the participants is therefore 
the same for the entire study sample. Information bias might also appear if the participants 
report incorrect information (110). Such a systematic error may result in misclassification. 
However, in the present studies, we do not think serious misclassification is a significant 
problem. Overall, we see no indications of serious differential misclassification in the 
included studies. 
 
4.1.3 Assessment of Helicobacter pylori 
The presence of H. pylori was assessed by detection of bacterial antigen in stool samples with 
a monoclonal immunoassay amplification method (“Hp Star”, Dako Cytomation, Glostrup, 
Denmark) strictly according to the manufacturer’s instructions. This method has been shown 
to have a sensitivity and specificity of more than 90% in adults as well as children (47), (111) 
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, and 98% and 94%, respectively, in adult patients in our region where the test has been 
validated (68). Unfortunately, and as far as we know, the test is not validated in children in 
our region, has been so elsewhere (112), (113), (41). This test and the serological antibody 
test are the most commonly used non-interventional test for diagnosis of H. pylori in our 
country. Compared to the blood test the faecal antigen test can detect the bacterium, whereas 
the blood antibody test has the disadvantage that antibodies are present in blood also after 
eradication of the bacterium. The disadvantage of using a stool test is the psychological 
aspects of the sampling. This was apparently the main cause of the low participation rate in 






5 Discussion of main results 
5.1 H.pylori and reflux disease  
In our study we have documented that the presence of H. pylori independently protects 
against reflux symptoms in men but not in women. Moreover, BMI is an independent risk 
factor for gastro-esophageal reflux symptoms among healthy female adults, but contributes 
only to a minor part of the variation in these symptoms.  
The issue of H. pylori and its role on reflux disease has been extensively studied with 
contradictional results (84). Unfortunately, there are few population based studies covering 
this issue. Our population based study is in contrast to a population-based study from Norway 
that could not find such an association (90). These discrepancies are hard to explain.  A 
definite plausible explanation of this discrepancy could be differences in assessment of H. 
pylori: stool test versus serum antibody test. A protective effect of H. pylori has been 
proposed earlier but not documented, the proposed protective mechanism being that H. pylori 
attenuates the potency of the gastric reflux in patients with corpus predominant gastritis (84). 
Finally, the diverging results of H. pylori to protect reflux symptoms in men and women is 
surprising and also hard to explain.  
 
We also found that BMI was an independent risk factor for the development of gastro-
esophageal reflux symptoms. BMI as an independent risk factor for reflux symptoms was 
only observed in younger adult women. Moreover, in agreement with a report by Nocon et al. 
(114), age was also an independent factor for reflux, although also only observed in women. 
As reported by Corley & Kubo (115), BMI-independent associations were observed in the 
white, but not in the black population. Therefore, the discrepancies observed in studies of 
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associations between reflux and BMI may be accounted for by differences in age, gender, 
ethnicity and geographical factors. 
 
5.2 H.pylori and obesity 
The distribution of infection in the various BMI classes is presented in Figure 1. There were 
no significant associations between the H. pylori status and the BMI classes among the 
females and among the males. It should be noted that the number of observations are low in 
the upper BMI classes, and most likely we have a statistical power problem. 
 
Figure 1. Relationships between H. pylori infection in the various BMI classes and the 
corresponding statistic analyses 
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H.pylori status was not associated to any of the BMI classes (p=0.67). This agrees with 
findings in another large population based study, the National Health and Nutrition 
Examination Survey (101). However, this is a controversial issue. 
 
In a meta-analysis of 49 studies in Europe, Japan, US and Australia that found an inverse 
correlation between H. pylori infection and BMI (103). Moreover, this association to H. pylori 




Finally, in a recent published review, the authors concluded that the increasing eradication of 
H. pylori during the last decade was a contributing causal factor to the obesity epidemic in the 
Western world (103). There are no obvious explanations of the discrepancies between these 
studies. Obesity is a multifactorial condition, and it seems strange that H. pylori should play a 
pivotal role in the energy balance in humans. Therefore, there is need for more studies to 
elucidate a potential causal relationship between H. pylori infection and BMI, and at least 
there is still a need of further population based cross-sectional and prospective studies.  
 
5.3 H. pylori infection and functional bowel symptoms  
In our study of the testing various risk factors to functional bowel disease; H. pylori infection 
was not associated to this condition, whereas female and low age were positively associated. 
The cause of IBS is unclear, but etiological factors such as genetic, food intolerance and gut 
microbiology including post-infection IBS has been proposed with visceral hypersensitivity as 
the common pathophysiological mechanism (94). The association between H. pylori infection 
and IBS is not settled. H. pylori infection has been shown to be a risk factor for IBS in one 
study (95) but no association in three other reports (96), (97), (98). There are very few larger, 
population-based studies that have addressed this issue. In a Chinese population based study 
of 18000 subjects no association between H. pylori and IBS was found (116). It should 
however, be mentioned one 10 year prospective population based study of some 8500 subjects 
found that a H. pylori infection predicted the likelihood of a later IBS consultation (95). In 
conclusion, so far there is no good evidence for an association between H. pylori infection and 
functional bowel disease, but there is a need for more population based studies before a firm 
conclusion can be made. 
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5.4 H. pylori and prevalence 
In our population with apparent high hygiene status the transmission of H. pylori infection 
first starts in the young and with an apparent peak in the sixties.  H. pylori infection was 
nearly not observed among children. Some few previous fecal antigen-based tests studies in 
children have been performed, finding prevalence figures from7 % to 47 % (112), (113), (41), 
(52).  Of interest is to note that our prevalence of 0,6% equals the serology based Dutch study 
in which the prevalence was 0.5% in children with two Dutch parents vs 2.6% in children 
with at least one non-Dutch parent (44).  
 
The prevalence of H. pylori infection in the adolescents was 20 %.  Prevalence studies from 
this age are harder to find in the literature. In Siberia, the prevalence in youths was 56.3% 
(54) and 42 % in an European multinational study (117), and around 50 % in Turkey  (55). 
Our data indicate that in adolescence in the 21
th 
century with high socio-economic and health 
standard, there is a so far unknown life-style factor(s) increasing the risk for transmission of 
H. pylori.  It must be emphasized that a cohort effect cannot be ruled out, and if so, the 
mothers’ prevalence must differ significantly in the two cohorts 0-11 and 12-17, which indeed 
was documented. Therefore, a follow-up study is needed to elucidate a potential transmission 
route from mother to child, which would be highly reduced with mothers of low rate of H. 
pylori infection. 
 
Although our data from adolescents are weak due to low participation rate, we can 
hypothesise that if all the 233 non-respondent teenagers had tested negative, the prevalence 
would still be 3%. Moreover, there can be little doubt that the first positive tests of H.bacter 




In our adult population the prevalence of H pylori was 33 % and lower than reported from 
most of the rest of the world with a range from 30 to > 50 % (118) review. The prevalence of  
H pylori in the adult populations is decreasing. Population studies from the community of 
Sørreisa showed a prevalence of 42 % in 1987 (57) to 33 % 17 years later (58). (see table 1). 
There is now well documented that the prevalence of the H pylori infection is decreasing 
worldwide in the start of the 21
th
 century, especially in countries with high hygiene standards. 
It appears that the highest contribution to the decreasing prevalence is among children.  
 
The strength of this study is the population-based prevalence measurements in all age groups, 
in two populations with similar socioeconomic background, and with a homogenous ethnicity. 
Moreover, we have based our data on an antigen-based H. pylori test with high sensitivity and 
specificity. Yet there are areas with some weakness. First, the participation from the 
adolescence group was low. The prevalence data of H. pylori infection from this group is 
uncertain, but the lowest possible prevalence would still be 3% if all the 205 non-participating 
subjects tested negative. Therefore, we have strong evidence from this study that H. pylori 
infection first occurs in the young. Another weakness of our study is that more 
comprehensible data would have been available if a family-based prevalence study had been 
performed in H. pylori positive subjects. 
 
In conclusion, the world-wide tendency of reductions in the prevalence is most likely 
associated to increased hygiene standard. The very high hygiene standard in the mother-child 
care typical for the Westernized societies may contribute to the world-wide reductions in the 
prevalence of H pylori especially in childhood. According to our data, it remains unresolved 




5.5 H. pylori and transmission routes 
In our study we searched for several potential transmission routes of the H pylori infection. In 
univariat analyses we found that risk factors for transmission were out-door toilette, private 
well and farm animals. These findings were as proposed from previous studies.  Thus, faecal 
animal H. pylori has been one of the most frequent proposed sources (22), and the primary 
transmission route via drinking water and thereafter intrafamiliar H pylori transmission (23). 
It should be mention that these risk factors were not independent of age. This may be 
explained by the fact that all potential risk factors tested are so tightly associated to age, that 
any independency cannot be expected. Despite this, our data indicate that H pylori comes 
from animal sources that may be of clinical importance associated to hygiene standards such 
as private water supply and tight contact with farm animals. Of interest to note was that the 
population without breast feeding as child was not associated to H pylori infection. Most 
studies agrees that breast feeding has a protective effect in a less economically developed 
setting (33). Most likely, in populations with high hygiene standard there is no transmission 
whether or not breast feeding is practised. In conclusion, in our population with high hygiene 
standard the transmission of H pylori infection may come from animals, out-door toilets and 






6. Conclusion and implications 
 
6.1 Conclusions 
In our study we have documented that the presence of H. pylori independently protects 
against reflux symptoms in men but not in women 
 
We could not find any significant association between H. pylori infection and body weight 
classes according to BMI including obesity 
 
We could not find any significant association between H. pylori infection and functional 
bowel symptoms 
 
The prevalence of H. pylori is low in our population with high hygiene standard due to low 
transmission rate in young age groups. 
 
H. pylori transmission is associated with low sanitary standards, such as animal contact, 






According to our conclusions, and if these are fully validated, the following implications can 
be proposed 
1. In men in our region with HP H. pylori infection without any apparent symptoms due 
to the infection, there is no need to eradicate the bacterium - at worst case the patient 
can become suffering from reflux disease 
2. Despite high hygienic conditions, there is an increased risk to be transmitted from H. 
pylori in young age, especially from adolescence on, where the environmental factors 
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Ungdom mellom 12 og 17 år !     Reg.nr…………………… 
Vil du delta i et forskningsprosjekt om mageplager? 
  
Mageplager er svært vanlige i befolkningen. Noen av disse mageplagene skyldes den såkalte ”magesårsbakterien” 
Helicobacter pylori. Selv om det nå snart er 20 år siden man fant denne bakterien i magesekken hos pasienter med magesår, er 
det fortsatt mye man ikke vet om bakterien. Hos noen vil den forårsake sykdom, men hos de fleste vil den sannsynligvis ikke 
det. Forholdene omkring smitteveier og smittemåte er ikke ordentlig avklart. Antagelig smittes man allerede som barn fra 
familiemedlemmer eller lekekamerater, og beholder deretter bakterien i magesekken til voksen alder, men dette vet vi ikke 
sikkert. Vi håper at dette forskningsprosjektet skal kunne gi svar på noen av disse spørsmålene. 
 
Den viktigste delen av prosjektet er å kartlegge forekomsten av bakterien Helicobacter pylori og andre mikrober hos friske 
personer i alle aldre. Til dette trenger vi en avføringsprøve slik det er angitt på vedlagte prøveglass, og som kan sendes inn i 
vedlagte ferdig frankerte konvolutt. I tillegg ønsker vi at vedlagte spørreskjema blir besvart og returnert. 
 
Forskningsprosjektet er vurdert av Personvernombudet for forskning, Norsk samfunnsvitenskaplig datatjeneste AS. Regional 
Etisk Komité for Medisinsk Forskningsetikk har vurdert prosjektet og har ikke innvendinger mot gjennomføringen.. 
 
Det er frivillig å delta, og du kan trekke deg fra undersøkelsen til enhver tid uten begrunnelse. Om du ikke ønsker å delta, eller 
om du trekker deg senere, vil det ikke få noen betydning for ditt forhold til helsevesenet. Innsamlede data om din person vil da 
bli slettet.  
 
Dataene som blir samlet inn, vil bli  behandlet strengt fortrolig, og ingen utenom forskningsgruppen vil få vite hva du har svart. 
Resultatene vil bli oppbevart på isolert datasystem hvor personidentifikasjon er erstattet av registreringsnummer. 
Avføringsprøvene fryses og oppbevares med det samme registreringsnummeret. Dette nummeret viser til et personregister som 
oppbevares adskilt fra det øvrige materialet.   
 
I tillegg til opplysningene om mageplager som du gir i  spørreskjemaet, ønsker vi å kunne innhente opplysninger om 
mageplager som finnes i din journal på legekontorene hos fastlegene, og i eventuell sykehusjournal, f. eks. tidligere 
mageoperasjoner, røntgen-undersøkelser, magesårbehandlinger, andre vesentlige sykdommer.  
 
Dette prosjektet vil vare til 1. januar 2015. Innen den tid kan noen av dere bli spurt om å delta i oppfølgningsprosjekter for å 
studere årsaksforhold for visse magesykdommer. Det er også mulig at dataene, i et evt. nytt delprosjekt, vil bli koblet til 
dataene i andre person- og helseregistre, for eksempel kreftregistret eller folketellingen, for å få mer kunnskap om eventuelle 
sammenhenger mellom magebakterien og utvikling av annen sykdom.  Hvis det ikke innhentes samtykke om noe annet, vil alle 
data anonymiseres i 2015.   
 
 
All fremtidig bruk av opplysninger og prøver vil bare skje etter godkjenning fra Datatilsynet og såfremt Regional Etisk Komité 
for Medisinsk Forskningsetikk ikke har innvendinger mot det. Du har innsynsrett i de opplysninger som registreres om deg.  
 
Forskningsresultatene vil bli publisert i medisinske tidsskrifter, og et sammendrag vil bli presentert i lokale medier, men ingen 
opplysninger vil her kunne etterspores til enkeltpersoner. Alle deltagere vil kunne få skriftlig beskjed om resultatet av testen på 
forespørsel til prosjektleder. 
 
Vi ber deg bekrefte om du ønsker å delta i de forskjellige delene av prosjektet slik de er beskrevet på neste side. 
 
Hvis du ikke ønsker å delta i prosjektet og vil unngå purring, kan du sette kryss i ruten her:   og returnere skjemaet på side 2. 
Du vil da ikke få purringer senere. 
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Ungdom 12 - 17 år       Registeringsnummer:……………………….                   
 
Samtykkeerklæring Bodø Helicobacter– sendes inn sammen med 
spørreskjemaet i hvit svarkonvolutt 
 
Jeg har lest informasjonen i forespørselen og : 
 
1.  Samtykker i å delta i undersøkelsen ved å svare på spørreskjemaet.  Ja  Nei 
2. Samtykker i å sende inn avføringsprøve til undersøkelse for mikrober   Ja  Nei 
3. Samtykker i at opplysninger om mageplager og undersøkelser/ 
behandling for disse kan innhentes hos primær-/fastlege og hos sykehus. 
 Ja  Nei 
4. Samtykker i å eventuelt bli kontaktet innen 1. januar 2015 med 
forespørsel om nye opplysninger eller undersøkelser 
 Ja  Nei 
5. Samtykker i at resultatene mine (etter godkjenning fra datatilsynet) kan 
settes sammen med opplysninger om meg i andre registre til bruk i 
eventuelle nye delprosjekt/forskning om magelidelser. Det kan være 
registre om helse, trygd og sykdom. Det kan også være registre om  
inntekt, utdanning og yrke samt opplysninger fra tidligere 
helseundersøkelser. Eksempler på slike registre er Kreftregistret, 
Statistisk Sentralbyrå,  Rikstrygdeverket. I disse tilfeller blir navnet og 
personnummeret mitt fjernet når dataene blir analysert 












Foreldre/foresattes navn __________________________ og underskrift ________________________ 
 
 
Sndes inn snarest mulig i vedlagte ferdig frankerte hvite svarkonvolutt 
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Ungdom 12 - 17 år       Registeringsnummer:……………………….                   
 
Samtykkeerklæring Bodø Helicobacter – ditt eksemplar             
 
Jeg har lest informasjonen i forespørselen og : 
 
1.  Samtykker i å delta i undersøkelsen ved å svare på spørreskjemaet.  Ja  Nei 
2.  Samtykker i å sende inn avføringsprøve til undersøkelse for mikrober   Ja  Nei 
3.  Samtykker i at opplysninger om mageplager og undersøkelser/behandling 
for disse kan innhentes hos primær-/fastlege og hos sykehus. 
 Ja  Nei 
4.  Samtykker i å eventuelt bli kontaktet innen 1. januar 2015 med 
forespørsel om nye opplysninger eller undersøkelser 
 Ja  Nei 
5.  Samtykker i at resultatene mine (etter godkjenning fra datatilsynet) kan 
settes sammen med opplysninger om meg i andre registre til bruk i 
eventuelle nye delprosjekt/forskning om magelidelser. Det kan være registre 
om helse, trygd og sykdom. Det kan også være registre om  inntekt, 
utdanning og yrke samt opplysninger fra tidligere helseundersøkelser. 
Eksempler på slike registre er Kreftregistret, Statistisk Sentralbyrå,  
Rikstrygdeverket. I disse tilfeller blir navnet og personnummeret mitt fjernet 
når dataene blir analysert 
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VEDLEGG TIL AVFØRINGSPRØVE – SENDES INN I VEDLAGTE FERDIG 
FRANKERTE BRUNE SVARKONVOLUTT 
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1. Registreringsnr:  
 
  
2. Er du født i Norge? 1 Ja  
2 Nei 
   
3. Hvis du er født i annet land enn Norge? Hvilket?______________________ 
   
4. Er dine foreldre født i Norge?                                  Mor 1 Ja  
2 Nei 
                                                                                            Far 3 Ja  
4 Nei 
   
5. Hvis en av eller begge foreldrene dine er  




   
Mageplager   
6. Har du noen gang hatt smerter  eller ”verk” i magen som 
har vart i minst 2 uker?  
(omgangssyke (reksjuke) regnes ikke med).   
1 Ja 
2 Nei (hvis nei gå til pkt.9) 
 
   
7. Hvis Ja i spørsmål 6, har du hatt smertene;  
(sett bare ett kryss)  
1 Ukentlig ? 
2 Månedlig ? 
3 Årlig eller sjeldnere ? 
   
8. Hvis Ja i spørsmål 6, hvor satt smertene eller ”verken” 
(sett bare ett kryss)    
1 i øvre del av magen ? 
2 i nedre del av magen ? 
3 i hele magen ? 
   
9. Har du noen gang hatt sure oppstøt, halsbrann  eller 
brystbrann  nesten daglig i minst en uke?  
1 Ja  
2 Nei (Hvis Nei, gå til pkt 11) 
   
10. Hvis Ja i spørsmål 9, har du hatt disse plagene  
(sett bare ett kryss) 
1 Ukentlig? 
2 Månedlig? 
3 Årlig eller sjeldnere? 
   
Bruk av helsetjenester   
11. Har du noen gang søkt fastlege på grunn av sure oppstøt, 
halsbrann, brystbrann, smerter eller ”verk” i magen? 
1 Ja 
2 Nei  
g Husker   ikke 
   
12. Har du noen gang vært henvist til, eller innlagt i sykehus 
på grunn av sure oppstøt, halsbrann, brystbrann, smerter eller 
”verk” i magen?  
1 Ja 
2 Nei (Hvis Nei, gå til pkt 20) 
g Husker   ikke 
   
13. Har du noen gang brukt syrenøytraliserende eller 
syrehemmende midler, daglig eller av og til?  
1 Ja 
2 Nei 
g Husker ikke 
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14. Er du operert  i magen? 1 Ja 
2 Nei (Hvis Nei, gå til pkt. 16) 
 
15. Hvis Ja i spørsmål 14 Av hvilken årsak _________________________ 
 
Ved hvilket sykehus_______________________ 
 




16. Oppgi din  høyde og vekt nå: Høyde uten sko ______cm 
 
Vekt uten klær _______kg 
   
Slekt   
17. Hvor mange søsken  har du?  Antall______ 
   
18. Hvilket nummer er du i rekken av søsken?   
(Eksempel; Hvis søskenflokken består av 2 storebrødre, deg 




Nummer_______           av_______ 
   
19. Har noen av disse i din familie hatt magesår?  
(Sett evt. flere kryss) 
1 Ektefelle eller samboer  
2 mor, far, søsken eller barn 
3 Ingen 
4 Vet ikke 
   
20. Angi, såfremt du kan, om du som barn fikk: 
(Sett bare ett kryss)  
1 Brystmelk 
2 Kunstig ernæring (flaske) 
3 Begge deler 
4 Vet ikke 
   
Fysisk aktivitet   
21. Hvor ofte mosjonerer eller deltar du  i fysisk trening av 
minst 20 minutters varighet og slik at du blir svett eller 
andpusten? 
1  Sjelden eller aldri 
2  Ukentlig 
3  Flere ganger i uken 
4  Daglig 
     
Medisin    
22. Har du i løpet av de siste 3 måneder brukt penicillin  
eller andre antibiotika? 
1 Ja 
2 Nei (Hvis Nei, gå til pkt.24 ) 
   
23. Hvis Ja i spørsmål 22 angi dato; 
(husker du ikke tidsrom eller navn skriv ”?” på linjen)  
fra_____ til_____   
 




24. Hvor mange familiemedlemmer (deg selv medregnet)  
bor i din husstand?  
 
Antall________ 
   
25. Er noen i din husstand 11 år eller yngre? 1 Ja 
2 Nei 
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26. Har du/din familie hatt noen form for husdyr/kjæledyr? 1 Ja 
2 Nei  
   
27. Hvis ja i spørsmål 26 angi da hvilket dyr og i hvilken periode i forhold til din egen alder 
 
f. eks Husdyr ___hest__________     fra jeg var __5_  til _8__  år 
 
Husdyr ________________     fra jeg var ____  til ____  år 
 Husdyr ________________     fra jeg var ____  til ____  år 
 Husdyr ________________     fra jeg var ____  til ____  år 
 Husdyr ________________     fra jeg var ____  til ____  år 
 Husdyr ________________     fra jeg var ____  til ____  år 
   
f. eks Kjæledyr__katt__________     fra jeg var _6___  til __12_  år 
 
Kjæledyr_______________     fra jeg var ____  til ____  år 
Kjæledyr_______________     fra jeg var ____  til ____  år 
Kjæledyr_______________     fra jeg var ____  til ____  år 
Kjæledyr_______________     fra jeg var ____  til ____  år 
Kjæledyr_______________     fra jeg var ____  til ____  år 
 
(Nummereringen er ikke helt fortløpende av datatekniske årsaker). 
 
